Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Denosumab biosimilar by Samsung Bioepis for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis. According to...
Pembrolizumab biosimilar by Samsung Bioepis for Non-Small Cell Lung Cancer: Likelihood of Approval
Pembrolizumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Non-Small Cell Lung Cancer. According...
Denosumab biosimilar by Samsung Bioepis for Post Menopausal Osteoporosis: Likelihood of Approval
Denosumab biosimilar is under clinical development by Samsung Bioepis and currently in Phase III for Post Menopausal Osteoporosis. According to...